Bristol Myers Squibb stock rises 0.41 percent on October 7

Published on 10/07/2026 at 16:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bristol Myers Squibb stock traded at USD 59.84 on October 7, 2026, up 0.41 percent. Q2 revenue reached USD 12.97 billion, 5.7 percent above the prior year.

Bristol Myers Squibb, US1101221083, Illustration mit AI erstellt.

Bristol Myers Squibb (ISIN US1101221083) stock was trading at USD 59.84 on the NYSE on October 7, 2026, up 0.41 percent from the previous close. The move leaves the shares 12.82 percent below their 52-week high of USD 68.64, while the company remains valued at USD 122.2 billion.

Revenue provides operating support

The latest reported quarter delivered USD 12.97 billion in revenue, up 5.7 percent from the year-earlier period. According to MarketBeat on October 5, 2026, Bristol Myers Squibb reported quarterly EPS of USD 2.04 against a USD 1.60 consensus estimate. The USD 0.44 beat gives the stock a measurable earnings cushion even as pipeline concerns weigh on sentiment.

The quarter also compared favorably with the prior-year EPS of USD 1.46, according to MarketBeat. Bristol Myers Squibb's FY 2026 guidance calls for EPS of USD 6.750-7.000, placing the latest quarter within a broader earnings framework rather than making it a standalone signal.

CAMZYOS expands the growth portfolio

On September 30, 2026, the U.S. Food and Drug Administration approved CAMZYOS for adults and pediatric patients weighing at least 30 kilograms with symptomatic obstructive hypertrophic cardiomyopathy. Bristol Myers Squibb said the approval was supported by the Phase 3 SCOUT-HCM trial, which enrolled 44 adolescent patients.

The approval broadens a cardiovascular asset while the company manages pressure from patent expirations affecting established medicines. The same release reported a CAMZYOS treatment group of 23 patients versus 21 in the placebo group, with a mean provoked LVOT-gradient change of minus 49.4 mmHg versus minus 1.8 mmHg.

Analyst targets remain above the quote

According to Financhill, 28 analysts assign Bristol Myers Squibb a Hold consensus and an average 12-month price target of USD 66.71. That target lies 11.48 percent above the USD 59.84 intraday price, a gap that reflects upside expectations alongside the risks already priced into the stock.

MarketBeat reported on October 5, 2026, that Leerink Partners cut its rating from Outperform to Market Perform and reduced its price target from USD 73.00 to USD 59.00. The revised target sits below the current quote, making clinical execution an important counterweight to the recent operating figures.

Stock trades above its yearly low

Bristol Myers Squibb stock was trading at USD 59.84 on October 7, 2026, with an intraday range of USD 59.01 to USD 59.91. The 52-week range of USD 42.52 to USD 68.64 places the shares 40.72 percent above the yearly low and 12.82 percent below the yearly high.